PT-141 and melanocortins
Melanotan II in Canada: Mechanism, Clinical Evidence and Safety Warnings
EC
· 2 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 6 sections
Quick answer: Melanotan II is an investigational melanocortin receptor agonist, not an approved tanning medicine in Canada. Receptor activity does not establish a safe cosmetic outcome.

The melanocortin family
Melanocortin receptors participate in pigmentation, energy balance and other physiological pathways. Melanotan II has activity beyond a single receptor, making broad physiological effects and unwanted effects biologically plausible.
What the human literature can tell us
Early research involved limited and generally small studies. These do not provide a strong basis for population-wide safety, long-term dermatological outcomes or claims that use is preferable to sun exposure. Cosmetic outcomes are not substitutes for validated cancer-risk assessment.
Why adverse-event reporting matters
Reports of nausea, flushing, pigment changes and other problems should not be dismissed as proof of activity. Products sourced outside authorized drug channels add uncertainty about identity, impurities, sterility and dose consistency.
Canadian regulatory context
Health Canada has specifically named melanotan compounds in its warning about unauthorized injectable peptides. Readers seeking medical advice about pigment changes or adverse effects should use qualified clinicians, not online dosing forums.
Frequently asked questions
Is Melanotan II authorized in Canada as a tanning drug? No.
Does a darker tan establish safety? No. Cosmetic pigmentation is not a validated safety endpoint.
Further reading
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
